Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04948099 · ClinicalTrials.gov registry record · Phase 1
A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT04948099 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 73 participants.
The verdict
NCT04948099, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
A first-in-human study to evaluate the safety and tolerability of escalating, single and multiple ascending doses of VIB1116 in adult participants with rheumatic diseases.
Interventions
- DRUG Placebo
- DRUG VIB1116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-07-06 |
| Est. Completion | 2023-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04948099
The ClinicalTrials.gov registry entry for NCT04948099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04948099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04948099 about?
NCT04948099 is a clinical study titled "A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases". A first-in-human study to evaluate the safety and tolerability of escalating, single and multiple ascending doses of VIB1116 in adult participants with rheumatic diseases.
What is the current status of trial NCT04948099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2021-07-06. Estimated completion is 2023-07-03.
What interventions are being tested in trial NCT04948099?
The interventions under investigation include: Placebo (DRUG), VIB1116 (DRUG).
Who is sponsoring clinical trial NCT04948099?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.